Pharmalittle: We're reading about an FDA-UniQure feud, Pfizer's 'problem' with the agency, and more The FDA concluded that UniQure's experimental Huntington’s treatment was not providing benefit for patients based on existing clinical data

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about an FDA-UniQure feud, Pfizer’s ‘problem’ with the agency, and more news.. statnews.com/pharmalot/20... #pharma #FDA #China #UniQure #Intellia #biotech #Pfizer

The Small Purpose: Why the Future of Ageing is Contentment, Not Just Longevity Moving beyond the "chase" of longevity to build the human infrastructure of the Silver Economy.

Ageing is more than a tech challenge; it’s a call to build human infrastructure centered on contentment and stability, rather than just longevity.

Full Reflection:
open.substack.com/pub/agetecha...

#AgeTech #Longevity #ASEAN #Intellia

Gene editing stocks surged after Bloomberg reported the FDA plans to streamline approvals for gene editing therapies.

#CRSP #CRSPStock #CRISPR #CRSPNews #CRSPStockNews #CRISPRTherapeuticsStock #CRISPRStock #GeneEditing #Biotech #GeneTherapy #FDA #DrugApproval #Editas #Intellia
$CRSP

Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause - Biotech Industry Examiner Standfirst: A hospitalised patient with a Hy’s-law-like profile has forced Intellia to pause two late-stage CRISPR studies in ATTR amyloidosis. The central

#Intellia has paused two Phase 3 ATTR studies after a Hy’s-law-like liver signal. The core question: product-specific risk or platform overhang for in-vivo editing? Here’s the investor read + what to watch next:
biotech.industryexaminer.com/intellia-cri...

#Biotech #CRISPR #ClinicalTrials #TechNews

Pharmalittle: We're reading about Organon's CEO resigning, Cigna ending some rebates, and more Cigna Group will eliminate prescription drug rebates in many of its commercial health plans in 2027, a practice that has drawn the ire of President Trump

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about Organon’s CEO resigning, Cigna ending some rebates & more news.. statnews.com/pharmalot/20... #pharma #rebates #fraud #wholesalers #generics #Organon #Intellia #Novartis

Intellia stock tumbles on safety concerns Investing.com -- Shares of Intellia Therapeutics (NASDAQ: NASDAQ:NTLA) plunged 19% following a safety update from its ongoing Phase 3 MAGNITUDE study. The clinical trial, which is evaluating the company’s gene-editing therapy nex-z for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM), reported a case of asymptomatic Grade 4 elevations in liver transaminases in one patient. The SEC filing dated May 28, 2025, detailed the current status of Intellia’s Phase 3 studies, including the MAGNITUDE study, which has enrolled approximately 365 out of an expected 765 patients. The adverse event in question appears to be resolving without hospitalization or medical intervention, with liver enzyme levels improving. Despite this incident, Citizens JMP analyst Silvan Tuerkcan maintained a Market Perform rating on Intellia, suggesting that the adverse event’s disclosure might lead to volatility but that several clarifications from management could mitigate concerns. BofA Securities analyst Greg Harrison, while lowering the price target to $39 from $43, reiterated a Buy rating, noting the potential overhang on safety until more data becomes available. H.C. Wainwright’s Mitchell S. Kapoor continued to support a Buy rating with a $30 price target, considering the rarity of the event and its potential acceptability in the risk-benefit profile of nex-z. Cantor Fitzgerald’s Rick Bienkowski, maintaining an Overweight rating and a $65 price target, commented on the post-market reaction to the news, stating, "we don’t think it’s quite time to panic yet, and see the sharp move as an overreaction." The company’s update also mentioned that enrollment for its other Phase 3 studies for hereditary angioedema and ATTRv-PN is progressing well, with expectations to complete enrollment within the given timelines and plans for potential commercial launches in the coming years. Investors reacted to the safety update with concern, given the importance of the ATTR-CM patient population for Intellia’s nex-z program. The company continues to monitor the adverse events closely as the MAGNITUDE study progresses.

Click Subscribe #Intellia #StockMarket #Investing #StockNews #SafetyConcerns

Grade 4 Liver Enzyme Elevation in Intellia’s Phase 3 ATTR Amyloidosis Trial Last night, Intellia filed a material event report ( 8-k ) with the SEC.  In there, they revealed a case of very high, grade 4 liver enzyme...

Grade 4 Liver Enzyme Elevation in Intellia’s Phase 3 ATTR Amyloidosis Trial (blog): rnaitherapeutics.blogspot.com/2025/05/grad... #ATTR-CM #Intellia $NTLA

Both #Intellia and #PrimeMedicine have whopping #short interests of around 30%. Tomorrow could be monumental.

Sleep well, shorts.

#Alnylam trades at a 50x market cap of #Intellia directly exposed to CRISPR for many of its high-value liver indications.

How on earth do they not have strategic option to #CRISPR, even through a 50:50-type partnership with a leading CRISPR Co if not in-house?

#RNAediting similar situation.

Lawsuit Filed Against Intellia Therapeutics Highlighting Alleged Securities Fraud Impacting Investors A new class action lawsuit against Intellia Therapeutics aims to recover losses for investors affected by alleged fraud. Key details and implications are discussed.

Lawsuit Filed Against Intellia Therapeutics Highlighting Alleged Securities Fraud Impacting Investors #United_States #New_York #Securities_Fraud #Joseph_E._Levi #Intellia

Levi & Korsinsky Alerts Intellia Therapeutics Investors of Class Action Lawsuit and Key Deadline Ahead Levi & Korsinsky has advised Intellia Therapeutics investors about a class action lawsuit related to alleged securities fraud. The deadline to act is approaching.

Levi & Korsinsky Alerts Intellia Therapeutics Investors of Class Action Lawsuit and Key Deadline Ahead #United_States #New_York #Levi_&_Korsinsky #Securities_Fraud #Intellia